Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
WUHAN,China,Jan. 3,2025-- Hanx Biopharmaceuticals,CO. Ltd,an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases,today